Microvioma is the Greek word for Microbiome, which constitutes >70% (in numbers) of what as human beings we are made of. Microvioma is a research-based Organization founded in verified science to participate in WHO’s One Health mission. We provide Microbiology-based solutions in several verticals contributing to One Health, including Human, Veterinary, and the Environment (incl. Agriculture).
Our Vision
To be one of the significant contributors to Healthy One Health.
Our Mission
- To provide Microbiology novel solutions in One Health and to those pursuing their goals in One Health such as
- Healthy Human Life,
- Healthy Animal Life,
- Healthy Foods (Agriculture) and
- Healthy Environment.
- To Invent / Discover through Drug Discovery that aids in improving the quality of life in all aspects of One Health.
- To Formulate Products that aid in improving the quality of life in all aspects of One Health by addressing the Microbiome.
- To provide solutions to microbiologically Qualified Products. (incl. environmental, varieties of Testing, etc.)
- To contribute to solving microbiological challenges scientifically through consultancies.
The Logo
Microvioma has been coined, by the founder of the private limited company, from the words ‘Microbe’ (and his deep rooted interest in Microbiology way back from college days) and ‘Vioma’ – Greek for ‘to live’.
When ARTEMYCKS (The creative Design Studio by Pran, Graphic Designer and Content Writer, currently based in Bengaluru and having worked in Singapore and Dubai. He can be reached on +91 97318 50889 or alternatively at pran583@gmail.com), was commissioned with the task of creating a logo for the company, Pran kept this in mind. He used a customized font-face based essentially on depictions of microbes as cylindrical structures with rounded ends. While keeping it minimal and simple, he used teal as the core colour to lend a clinical research/ laboratory flair to the creative.
The letter ‘o’ of ‘Vioma’ reflects the ‘cyclic’ triad of one-health, viz ‘healthy environment, healthy animals, healthy human beings’ which is the foundation and passionate scope of participation of the ambitious venture – Microvioma.
The colours are partly representative of the 17 Sustainable Development Goals (SDGs), as stipulated by the United Nations, which are an urgent call for action by all countries – developed and developing – in a global partnership. A blueprint for peace and prosperity for people and the planet, now and into the future.
The ‘o’ also denotes a safety water floatee that aims to represent microbes and research therein as potential ‘life savers’ for human wellbeing and existence.
Founder CEO
Dr. Maneesh Paul
Co-inventor
Antibiotic Enmetazobactam
Dr. Maneesh Paul, the Lead Co-inventor and Program Director of Enmetazobactam, is a clinical microbiologist who pursued basic and applied research discovering novel anti-infectives and characterising several microbial genes and proteins. He has translated scientific accomplishments and leadership through patents and publications.
He received his master’s degree in medical microbiology from Kasturba Medical College- MAHE and went on to undertake research for his Ph.D. from Gulbarga University supported by Jean-Claire Lee of Harvard Medical School, Boston USA.
As a Postdoctoral Fellow at Johns Hopkins School of Medicine, USA, he is trained in infectious diseases, specifically in molecular mechanisms of the pathogenesis of neonatal microbial meningitis esp. the E. coli (with Dr. Kwang Sik Kim), and M. tuberculosis (at Johns Hopkins Bloomberg School of Public Health with Dr. William Bishai).
Dr. Paul was also a Postdoc with Dr. Sirkka Asikainen at Umeå University, Sweden studying the role of A. actinomycetemcomitans in the pathogenesis of atherosclerosis collaborating with Dr. Casey Chen (Uni. S. California, USA), Dr. Scott Hultgren (Uni. Washington, St. Louis, USA), Dr. Staffan Normark (Karolinska Institute, Stockholm, Sweden), Pirkko Pussinen (Uni. Helsinki, Finland) and many others.
Dr. Paul was the ORISE Fellow with Dr. Margaret Bash at the Center for Biologics Evaluation and Research, USFDA, MD, USA working on reverse vaccinology of N. meningitidis and as an Industrial Fellow in the anti-infectives new drug discovery program at Dr. Reddy’s Laboratories Ltd, India.
For the longest time (since 2006) Dr. Paul has led the anti-infectives discovery research group at Orchid Pharma, India, and co-invented several pre-clinical candidates in anti-bacterial and anti-fungal space, including leading the Enmetazobactam program and out-licensing it at phase 1 to Allecra Therapeutics GmbH that is now approved by the USFDA, and EMA for Marketing (2024). This is the first India-invented NCE to have been approved by the two major Regulatory Agencies.
He led post-graduate evidence-based medical research at St. Martha’s Hospital, India in addition to continuing to advise several companies (2013-2018).
Dr. Paul has led trans-disciplinary research at Acharya Group of Institutions, Bengaluru (2018-2022), and enabled the process of Acharya Institutes becoming a research-based campus (proposed University) of academic excellence.
He became an AMR stewardship champion at the Gordon Conference (Ciocco, Italy) through the Antibiotic Action initiated by Dr. Laura Piddock.
He has served as a member of the AMR Committee (until 2022) of the Infectious Diseases Society of America (IDSA, USA).
He is currently (2024-2026) appointed as a member of the Strategic Advisory Committee of the UK Research and Innovation (UKRI) Initiative in Antimicrobial Resistance – PACE -AMR (Pathways to Antimicrobial Clinical Efficacy).
He founded Microvioma to address the challenges of AMR through Innovation, and Community Stewardship through AMRACE (AMR Action Collaborative Engagement). Microvioma also has a focus on finding innovative microbiota-based solutions towards Healthy Ageing, and Autism.
ADVISORS
Microvioma will collaborate with a team of Scientific Advisors who will drive the Anti-infective activities starting from Microbiology, Bioinformatics, Medicinal Chemistry, molecular biology, pharmacology, toxicology, regulatory affairs, quality assurance, clinical trials, marketing.
Dr. Srini Srinivasan
A Medicinal Chemist (Ph.D Western University, UK), he started his career in United States Pharacopeia as Scientist until retiring as Executive Vice President & Chief Science Officer. Certification of Pharmaceuticals (APIs), Dietary supplements. Excipients Globalization of organization activities through negotiations and merger Expert in CMC documents preparations , review and review of ANDA submissions, review of GMP audit using ICH Q7 Guidelines
After serving the United States Pharmacopeia for 29 years and most recently as Executive Vice President and Chief Science Officer, Dr Srinivasan has stepped down from the organization on May 1 2015. He is awarded the Honorary Membership of the United Sates Pharmacopeial Convention at the Convention.
LinkedIn : Srini Srinivasan | LinkedIn
Dr. Jagadish Mittur
An academic scientist with PhD in Microbial Genetics from Dublin, Ireland (1979), and16+ years each of Academic and Industry Experience across 5 countries (India, Ireland, USA, Germany & Australia), he led Biotechnology Facilitation Cell at Karnataka Innovation and Technology Society, Dept. IT BT and S&T, GOK, for 7 years to the growth of Biotech Ecosystem.
LinkedIn : Mittur Jagadish, PhD | LinkedIn
Research and development leader with over 30 years of experience working with industry (Unilever & ITC) and international organization CGIAR. Have over 15 patents in Beverages and foods. Ph D from Cambridge and Postdoc from York, UK.
LinkedIn : Navin Sharma | LinkedIn
Ms. Karon Shaiva
CMC, MMM, BE, DBF, DT&D, Six Sigma Green Belt (KPMG), ISO Internal Auditor, CSR (SI, Sweden), Faculty – Mentor (NEN- London Business School), PGD-Human Rights (Current)
Karon Shaiva is an award-winning social entrepreneur, writer, speaker and trainer on Social innovation, Partnerships for the SDGs, Shared Values and Peace. Karon firmly believes in the people-power of Citizenship, Entrepreneurship and Partnership to address some of the world’s most pressing issues. Karon has been deeply involved in health, education and environment as key drivers of women empowerment, community strengthening and sustainable development.
A Certified Management Consultant (CMC) with over 20 years’ experience in India and the USA, across IT, Education, Finance, Gemology and Social development sectors. Multifunctional expertise includes Research, Marketing, Communications, Media, Monitoring & Evaluation, Training and Development, Quality Assurance, Event Management, Alliances and Operations.
LinkedIn : Karon Shaiva | LinkedIn
Dr. Prekshna Gabriella
Ayurvedic Doctor whose passion is to look at life holistically as propagated by the Founder of Medicine – Acharya Shusrutha who advised on One-Health much before Modern medicine
Mr. Utkarsh Paul
A finance major from St. Joseph’s College of Commerce, he has industrial experience in the fields of sutainability and investment management. Currently pursuing his CFA charter, he specialises in management of organisational funds and investments. His understanding of the importance of financial management in an organisation combined with his affinity for sustainable living has enabled his interest in accelerating the growth of the concept of One Health
LinkedIn : Utkarsh Paul | LinkedIn
Dr. Maneesh Paul. S
- Co-inventor of the antibiotic Enmetazobactam (first antibiotic invented in India and given to the world)
- Masters from: Kasturba Medical College (MAHE), India
- Doctorate from Gulbarga University, India with Project support by Harvard Medical School USA
- Two Postdoctoral Fellowships in infectious diseases from: Johns Hopkins School of Medicine, Baltimore, USA, and Umeå University, Sweden
- Research Fellow: in meningitis at US FDA, Bethesda, USA, and in Antibiotic discovery at Dr.Reddy’s R&D, India
- Clinical Microbiologist at KIMS Hospital Research Centre
- As Chief Scientific Officer Mentored >100 medical postgraduates (DNB) at St. Martha’s hospital in 7 clinical disciplines
- Associate Director at Orchid Pharma and co-invented several pre-clinical candidates in infection, & Medical devices
- Publications: 34
- Patents: 44 worldwide from 5 Inventions
- Global Antimicrobial R&D Partnership Expert in WHO.
- IDSA, USA Subject matter expert.
- Until he started Microvioma in Aug 2022, he was driving research-based academic excellence at the Acharya group of Institutions
LinkedIn : Maneesh Paul. S (Satyaseela) | LinkedIn
Dr. Shridhar Narayanan
Passionate to make a difference in high social impact diseases, especially infectious diseases and AMR. Strong drug discovery and development background with contributions to 18 clinical candidates across infection, diabetes, oncology, inflammation, pain and CVD.
LinkedIn : Shridhar Narayanan| LinkedIn
Dr. Narayanan Surendran (Suri)
Suri has a B. Pharm (Hons) from BITS Pilani, India and PhD in Pharmaceutical Sciences from the University of Arizona, Tucson. He has over 24 years of experience in drug discovery and development with 3 patents, 20+ publications and 40+ presentations in various scientific conferences. He is the inventor of the granted US patent on the technology being developed by Ayma Therapeutics. His primary area of expertise is Drug Metabolism and Pharmacokinetics (DMPK). He is also the founder of RythRx Therapeutics LLC, an Ann Arbor based company focused on improving blood and platelet storage.
LinkedIn : Narayanan Surendran| LinkedIn
Ms. Rachana Urs
A Microbiology Postgraduate, intrigued by the Life-changing Potential of the Gut Microbiome, focuses on healing the Gut and maintaining Eubiosis to lead a Healthy Holistic Life.
LinkedIn: Rachana Urs | LinkedIn